Author:
Li Lu,Xie Hongliang,Wang Ling,Zhang Aolin,Mou Xuan,Lin Yifan,Ma Hongli,Wang Yu,Li Jian,Gao Jingshu,Wang Chi Chiu,Leung Ping Chung,Fan Xiaohui,Wu Xiaoke
Abstract
Abstract
Objective
To systematically review the clinical efficacy and safety of Chinese herbal medicine (CHM) with and without Western medicine (WM) for different severity of COVID-19.
Methods
CNKI, PubMed, Wanfang Database, ClinicalTrails.gov, Embase, ChiCTR and ICTRP were searched from 01 Jan, 2020 to 30 Jun, 2021. Two authors independently assessed all the randomized clinical trials (RCTs) for trial inclusion, data extraction and quality assessment. Meta-analysis was conducted using Review Manager software (RevMan 5.4.1). Evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Primary outcomes included total effectiveness rate. Secondary outcomes included improvements in symptom improvement and total adverse event rate. Different severity of COVID-19 patients was assessed in subgroup analysis. This study was registered with INPLASY, INPLASY202210072.
Results
22 high quality RCTs involving 1789 participants were included. There were no trial used CHM alone nor compare placebo or no treatment. Compared with WM, combined CHM and WM (CHM-WM) treatment showed higher total effectiveness rate, lower symptom scores of fever, cough, fatigue, dry throat and pharyngalgia, shorter mean time to viral conversion, better Computerized Tomography (CT) image and blood results, fewer total adverse events and worse conditions (P < 0.05). Subgroup analysis showed that the total effectiveness rate of combined CHM-WM group was significantly higher than WM group, especially for mild and moderate patients. No significant differences in mortality and adverse events were found between combined CHM-WM and WM treatment. No serious adverse events and long-term outcomes were reported.
Conclusion
Current evidence supported the therapeutic effects and safety of combined CHM-WM treatment on COVID-19, especially for patients with mild and moderate symptoms. Long-term effects of therapy are worthy in further study.
Funder
Natural Science Foundation of Zhejiang Province
Chinese Academy of Engineering Projects for COVID-19
Heilongjiang Province Urgent Project-6 for COVID-19
Publisher
Springer Science and Business Media LLC
Subject
Complementary and alternative medicine,Pharmacology
Reference78 articles.
1. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 Pneumonia in Wuhan. China JAMA Intern Med. 2020;180(7):934–43.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 Novel Coronavirus in Wuhan. China Lancet. 2020;395(10223):497–506.
3. WHO Health Organization. WHO Coronavirus (COVID-19) dashboard. https://who.sprinklr.com/.
4. Yue T, Fan B, Zhao Y, et al. Dynamics of the COVID-19 basic reproduction numbers in different countries. Sci Bull (Beijing). 2021;66(3):229–32.
5. Notice on novel coronavirus pneumonia diagnosis and treatment plan (Trial Version 7). National Health Commission, 2020-03-04. http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献